Anand joined Sofinnova in 2007 as a Principal. In 2014, he was promoted to General Partner. He focuses on working with entrepreneurs to build drug development companies that have the power to improve the lives of patients. Anand represents Sofinnova on the boards of Aclaris (ACRS), First Aid Shot Therapy, Merus, and Spark Therapeutics (ONCE). He led Sofinnova’s investments for Vicept Therapeutics (acquired by Allergan), Aerie Pharmaceuticals (AERI), Aclaris (ACRS), Civitas (acquired by Acorda), Prothena (PRTA), and Spark Therapeutics (ONCE). He played an important role in the firm’s investments in Amarin (AMRN), Nextwave Pharmaceuticals (acquired by Pfizer), Preglem (acquired by Gideon Richter), and SarCode (acquired by Shire).
Prior to joining Sofinnova, Anand worked at JP Morgan Partners in private equity and venture capital. Before joining the venture community, he was a consultant for McKinsey & Company’s healthcare practice, advising large pharmaceutical and biotech companies on core strategic issues. Anand has fourteen years of experience in biomedical research, consulting, and investing, and is the author of multiple peer-reviewed articles and abstracts. Frequently, he is an invited speaker on venture capital and industry panels.
Anand received his MD from Columbia University’s College of Physicians and Surgeons. He was an Echols Scholar and conducted National Institute of Health sponsored research on the outcomes, mechanisms, and pre-clinical development of therapeutic agents for stroke. He graduated Phi Beta Kappa from the University of Virginia with a BA in Political Theory through the Government Honors program. While in college, he spent three years as a firefighter for the Seminole Trail Fire Department.